Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | GAPDH | P04406 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15719546 | 0.84 | ALDH1A1 (0.43) | ALDH1A1EGFRGAAEPHX2MAPT | |
| SCHEMBL2029748 | 0.84 | PPARA (0.41) | ALDH1A1EGFRGAAEPHX2MAPT | |
| SCHEMBL691738 | 0.82 | HTT (0.44) | ALDH1A1EGFRGAAEPHX2MAPT | |
| SCHEMBL9666458 | 0.81 | PPARA (0.51) | ALDH1A1EGFRGAAEPHX2MAPT | |
| SCHEMBL20020213 | 0.79 | ALDH1A1 (0.47) | ALDH1A1EGFRGAAEPHX2MAPT | |
| SCHEMBL2828069 | 0.79 | KDM4E (0.44) | ALDH1A1EGFRGAAEPHX2MAPT | |
| SCHEMBL9665941 | 0.78 | PPARA (0.64) | ALDH1A1EGFRGAAEPHX2MAPT | |
| SCHEMBL6965688 | 0.78 | EPHX2 (0.40) | ALDH1A1EGFRGAAEPHX2MAPT | |
| SCHEMBL18623686 | 0.78 | NPC1 (0.50) | ALDH1A1MAPTSMN1; SMN2NPC1MEN1 | |
| SCHEMBL2824498 | 0.78 | ALDH1A1 (0.46) | ALDH1A1EGFRGAAEPHX2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110167944-B | Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors | 联合疗法公司 | 2024-08-23 | — | — | CN | claimed |
| US-8598154-B2 | Pyridyl-amine fused azadecalin modulators | CORCEPT THERAPEUTICS, INC. (US) | 2013-12-03 | — | — | US | claimed |
| EP-2609097-A1 | PYRIDYL-AMINE FUSED AZADECALIN MODULATORS | Corcept Therapeutics, Inc. (US) | 2013-07-03 | — | — | EP | claimed |
| US-20120220565-A1 | PYRIDYL-AMINE FUSED AZADECALIN MODULATORS | CORCEPT THERAPEUTICS, INC. (US) | 2012-08-30 | — | — | US | claimed |
| WO-2012027702-A1 | PYRIDYL-AMINE FUSED AZADECALIN MODULATORS | CORCEPT THERAPEUTICS, INC. (US) | 2012-03-01 | — | — | WO | claimed |
| US-20250188075-A1 | SUBSTITUTED HETEROCYCLIC CSNK1 INHIBITORS | THE BROAD INSTITUTE, INC. | 2025-06-12 | — | — | US | disclosed |
| EP-3645533-B1 | TDO2 AND IDO1 INHIBITORS | GENENTECH INC (US) | 2025-03-26 | — | — | EP | disclosed |
| CN-113330000-B | 3-Carbonylamino-5-cyclopentyl-1 FI-pyrrole compounds having inhibitory activity on CDK2 | 辉瑞公司 | 2024-12-24 | — | — | CN | disclosed |
| EP-4469457-A1 | SUBSTITUTED HETEROCYCLIC CSNK1 INHIBITORS | The Broad Institute Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| US-20240294506-A1 | CDK2 INHIBITORS | PFIZER INC. (US) | 2024-09-05 | — | — | US | disclosed |
| CN-110167944-B | Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors | 联合疗法公司 | 2024-08-23 | — | — | CN | disclosed |
| US-11773082-B2 | CDK2 inhibitors | PFIZER INC. (US) | 2023-10-03 | — | — | US | disclosed |
| CN-1068316-C | Process for synthesizing 5-methyl-isoxazole-3-carboxamide | KUNSHAN GENERAL PHARMACEUTICAL (CN) | 2001-07-11 | — | — | CN | disclosed |
| CN-1156723-A | Process for synthesizing 5-methyl-isoxazole-3-carboxamide | KUNSHAN GENERAL PHARMACEUTICAL (CN) | 1997-08-13 | — | — | CN | disclosed |
| US-5208251-A | Compounds for antiinflammatory agents, antiallergens, antiarthritic, antiulcer agents | WARNER-LAMBERT COMPANY (US) | 1993-05-04 | — | — | US | disclosed |
| US-5059614-A | NOVEL ISOXAZOLE AND ISOXAZOLINE COMPOUNDS WITH ANTICONVULSANT ACTIVITY PROCESS FOR THEIR PREPARATION AND THERAPEUTIC COMPOSITION CONTAINING THEM | NOVAPHARME (FR) | 1991-10-22 | — | — | US | disclosed |
| EP-0245825-B1 | STYRYL PYRAZOLES, ISOXAZOLES AND ANALOGS THEREOF HAVING ACTIVITY AS 5-LIPOXY-GENASE INHIBITORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | WARNER-LAMBERT COMPANY (US) | 1991-03-13 | — | — | EP | disclosed |
| US-4924002-A | REACTION WITH MOLYBDENUM CARBONYL AND HYDRAZINE | WARNER-LAMBERT COMPANY (US) | 1990-05-08 | — | — | US | disclosed |
| US-4877881-A | SUNSCREEN | WARNER-LAMBERT COMPANY (US) | 1989-10-31 | — | — | US | disclosed |
| EP-0245825-A1 | Styryl pyrazoles, isoxazoles and analogs thereof having activity as 5-lipoxy-genase inhibitors and pharmaceutical compositions containing them | WARNER-LAMBERT COMPANY (US) | 1987-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773082-B2 | CDK2 inhibitors | CDK2, CDK1, CCNI | ALDH1A1 2447/4885EGFR 225/4885GAA 2971/4885 |
| US-20240294506-A1 | CDK2 INHIBITORS | CDK2, CDK1, CCNI | ALDH1A1 2447/4885EGFR 225/4885GAA 2971/4885 |
| US-20120220565-A1 | PYRIDYL-AMINE FUSED AZADECALIN MODULATORS | NR3C1, NR3C2, NR5A2 | ALDH1A1 4358/4885EGFR 1428/4885GAA 4849/4885 |
| US-20250188075-A1 | SUBSTITUTED HETEROCYCLIC CSNK1 INHIBITORS | CSNK1A1, CSNK2A1, CSNK1A1L | ALDH1A1 1807/4885EGFR 475/4885GAA 1852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.